

JCO9 Rec'd PCT/ 1 2 MAR 2001

#5



PATENT  
Attorney Docket No. P03986US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Burkhard Göke  
SERIAL NO: 09/719,410  
FILED: December 12, 2000  
TITLE: GLUCAGON-LIKE PEPTIDE-1 IMPROVES THE ABILITY OF THE  
B-CELL TO SENSE AND RESPOND TO GLUCOSE IN SUBJECTS WITH  
IMPAIRED GLUCOSE TOLERANCE

Group Art Unit:  
Examiner:  
Confirmation No:

**INFORMATION DISCLOSURE STATEMENT  
BEFORE MAILING DATE OF EITHER A FINAL ACTION  
OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This information disclosure statement is being filed *before* the mailing date of either a final action under § 1.113 or a notice of allowance under § 1.311, whichever occurs first.

Attached are Forms PTO/SB/08A and 08B (formerly Form PTO-1449) listing the relevant art known to the applicant herein. Copies of the listed references are enclosed. The Examiner is requested to consider the references and make them of record.

Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

Applicant elects the option to pay the fee set forth in 37 C.F.R. sec 1.17(p) for submission of an information disclosure statement under § 1.97(c). A check in the amount of \$240.00 is enclosed.

---

CERTIFICATE OF MAILING

I hereby certify that the above correspondence was mailed to the Assistant Commissioner for Patents, Washington, D.C. 20231, as First Class mail, postage prepaid, this 6th day of March, 2001.


  
Edmund J. Sease

Authorization is hereby made to charge any additional fees required by this paper or credit any overpayment to Deposit Account 26-0084. A duplicate of this paper is attached.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. (Notice of January 9, 1992, 1135 O.G. 13-25, at 25.)

Respectfully submitted,



Edmund J. Sease, Reg. No. 24,741  
ZARLEY, McKEE, THOMTE, VOORHEES  
& SEASE  
801 Grand Avenue, Suite 3200  
Des Moines, Iowa 50309-2721  
Phone No. (515) 288-3667  
Fax No. (515) 288-1338  
**CUSTOMER NO: 22885**

03/19/2001 UEDUVIJE 00000130 09719410

01 FC:126

180.00 OP

Reg'n. Ref: 03/19/2001 UEDUVIJE 0012213600  
DAH:260084 Name/Number:09719410  
FC: 704 \$60.00 CR

- EJS/rl -

Attorneys of Record

+

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

(use as many sheets as necessary)

Sheet

1

of

2

Application Number

09/719,410

Filing Date

December 12, 2000

First Named Inventor

Burkhard Goke et al.

### Group Art Unit

Examiner Name

Attorney Docket Number

P03986US2

[illegible][illegible]

Examiner  
Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

<b>Application Number</b>	09/719,410
---------------------------	------------

<b>Filing Date</b>	December 12, 2000
--------------------	-------------------

First Named Inventor	Burkhard Goke et al.
----------------------	----------------------

Group Art Unit

Examiner Name

Attorney Docket Number	P03986US2
------------------------	-----------

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

T<sup>2</sup>

2 RACHMAN J ET AL: "Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM." DIABETOLOGIA, (1997 FEB) 40 (2) 205-11., XP002122529

3	CAVAGHAN M K ET AL: "Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance." JOURNAL OF CLINICAL INVESTIGATION. (1997 AUG 1) 100 (3) 530-7.. XP002122530 the whole document
---	---

4	BYRNE M M ET AL: "Glucagon - like peptide I improves the ability of the beta - cell to sense and respond to glucose in subjects with impaired glucose tolerance." DIABETES, (1998 AUG) 47 (8) 1259-65., XP002122530 the whole document
---	--

**Examiner  
Signature**

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**